Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping

Kostolanská, Katarína; Peš, Ondřej; Zendulka, Ondřej; Máchal, Jan; Juřica, Jan

doi:10.1007/s11696-019-00682-4

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to traditional PPIs, P‐CABs lead to very fast, competitive, reversible proton pump inhibition (Inatomi, Matsukawa, Sakurai, & Otake, 2016; Mori & Suzuki, 2019; Oshima & Miwa, 2018). P‐CABs are not metabolized by CYP2C19, but metabolized mainly by CYP3A4, resulting in less individual differences and reduced the adverse drug reactions (Denisenko et al, 2018; Kaartinen et al, 2020; Kostolanská, Peš, Zendulka, Máchal, & Juřica, 2019). Currently, there are two types of P‐CABs, vonoprazan (TAK‐438), and revaprazan, which are prescribed for the treatment of ARDs (Hunt & Scarpignato, 2015; Li, Qiao, Yue, Cai, & He, 2018; Sugano, 2018).…”

Section: Introductionmentioning

confidence: 99%

Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats

Peng

Shao

et al. 2022

Birth Defects Research

View full text Add to dashboard Cite

The novel potassium competitive acid blocker, KFP‐H008, developed to overcome the shortcomings of proton pump inhibitors. In this study, KFP‐H008 was administered by oral gavage at doses of 0 (control), 15, 45, and 150 mg/kg to Sprague–Dawley rats (24 animals per sex per group). Body weight, food consumption, mortality, sexual cycle, mating behavior, pregnancy, sperm motility, and relative organ weights were evaluated. In a concomitant toxicokinetic (TK) study (10 animals per sex per group), plasma TK parameters and tissue distribution of KFP‐H008 were tested. There were obvious effects at the dosage of 150 mg/kg to male rats with decreases of prostate weight and lower weight gain; to female rats with lower weight gain, hair off, and lower corpus luteum count. There were no effects on litter parameters. Time to reach maximum plasma concentrations for KFP‐H008 was between 0.5 and 1.0 hr for the 15 and 45 mg/kg groups, while for the 150 mg/kg group it had a delay to 2 hr. Overall, the NOAEL of KFP‐H008 was considered to be 45 mg/kg in both genders and the TK study shows that exposure (area under the curve) of male rats was about 1,091.0 ± 530.8 μg/Lhr and to female rats was 1,030.5 ± 512.5 μg/Lhr. Administration of KFP‐H008although reaches the reproductive organs, it demonstrated no significant effects on reproductive organs, it did not affect mating, fertility, pregnancy, growth, or morphologic development.

show abstract

Section: Introductionmentioning

confidence: 99%

Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats

Peng

Shao

et al. 2022

Birth Defects Research

View full text Add to dashboard Cite

show abstract

“…This enzyme acts as a pump to produce gastric acid and LNP inhibits the final step of biosynthesis of the enzyme. [4,5] Various analytical methods are available for the determination of LNP in pharmaceuticals, biological fluids and synthetic mixtures consisting of spectrophotometry/colorimetry, [6][7][8][9] potentiometry, [10,11] Fourier-transform infrared (FTIR) spectrometry, [12] capillary zone electrophoresis (CZE) [13] and high-performance liquid chromatography (HPLC) coupled with ultraviolet (UV), mass spectrometry (MS), [14,15] photo diode array (PDA), [16][17][18] and tandem mass spectrometry (MS/MS) [19,20] detectors. In addition, a limited number of comprehensive review articles have been published covering quantitative analysis of different PPIs including LNP in biological and pharmaceutical samples.…”

mentioning

confidence: 99%

Determination of lansoprazole in pharmaceuticals using flow injection with rhodamine 6G–diperiodatoargentate(III) chemiluminescence detection

et al. 2022

View full text Add to dashboard Cite

A chemiluminescence (CL) method based on rhodamine 6G (R6G)diperiodatoargentate(III) (silver(III) complex) reaction in acid solution is reported for the determination of lansoprazole (LNP) combined with a flow injection (FI) technique. The most likely mechanism for CL reaction was elucidated considering reported data, spectrophotometric and spectrofluorimetric studies. The weak CL reaction between R6G and silver(III) complex could be magnanimously increased in the presence of LNP with a limit of detection (LOD) of 0.002 mg L À1 (S/N = 3), a linear range of 0.01 to 10 mg L À1 (R 2 = 0.9997, n = 7), a relative standard deviation (RSD) of 1.2 to 3.2% (n = 4) and an injection throughput of 140 h À1 . No interference activity of commonly found excipients in LNP was detected. After LNP extraction from pharmaceutical samples, the recovery rate ranging from 93 to 110% (RSD, 1.4-3.3%, n = 4) was calculated. The results of the proposed flow CL method were assessed with a spectrophotometric approach applying paired Student's t-test and the calculated value (0.178) was lower than the distributed value (2.20) at a 95% confidence limit.

show abstract

CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants

et al. 2020

View full text Add to dashboard Cite

Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping

Cited by 3 publications

References 30 publications

Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats

Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats

Determination of lansoprazole in pharmaceuticals using flow injection with rhodamine 6G–diperiodatoargentate(III) chemiluminescence detection

CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants

Contact Info

Product

Resources

About